Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christo van Niekerk

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The New England Journal of Medicine|March 27, 2020
Telacebec (Q203), a New Antituberculosis AgentVeronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy SubjectsJeongjun Kim, Jinho Choi, Hwankyu Kang, et al.
Antimicrobial Agents and Chemotherapy|December 12, 2022
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B TrialJeongjun Kim, Jinho Choi, Hwankyu Kang, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsAndreas H Diacon, Rodney Dawson, Madeleine Hanekom, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The New England Journal of Medicine|March 27, 2020
Telacebec (Q203), a New Antituberculosis AgentVeronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2021
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy SubjectsJeongjun Kim, Jinho Choi, Hwankyu Kang, et al.
Antimicrobial Agents and Chemotherapy|December 12, 2022
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B TrialJeongjun Kim, Jinho Choi, Hwankyu Kang, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
Lancet (London, England)|July 26, 2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
American Journal of Respiratory and Critical Care Medicine|January 27, 2015
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquilineAndreas H Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsAndreas H Diacon, Rodney Dawson, Madeleine Hanekom, et al.
The New England Journal of Medicine|March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisFrancesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Pageof 1